GLPG0634 Shows Selective Inhibition of JAK1 and Maintained JAK-STAT Suppression in Healthy Volunteers

被引：0
|
作者：
Vanhoutte, Frederic [1 ]
Galien, Rene [2 ]
Vets, Eva [3 ]
Namour, Florence [2 ]
Vayssierre, Beatrice [2 ]
Van Rompaey, Luc [1 ]
Smets, Bart [1 ]
Brys, Reginald [1 ]
Wigerinck, Piet [1 ]
van 't Klooster, Gerben [1 ]
机构：
[1] Galapagos NV, Mechelen, Belgium
[2] Galapagos SASU, Romainville, France
[3] SGS, Antwerp, Belgium
来源：
ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2210
引用
收藏
页码：S862 / S863
页数：2
相关论文
共 50 条
  • [21] Selective inhibition of JAK1 shows promise for RA
    Collison, Joanna
    NATURE REVIEWS RHEUMATOLOGY, 2018, 14 (08) : 441 - 441
  • [22] Selective inhibition of JAK1 shows promise for RA
    Joanna Collison
    Nature Reviews Rheumatology, 2018, 14 : 441 - 441
  • [23] Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma
    Yang, Shuqun
    Luo, Chonglin
    Gu, Qingyang
    Xu, Qiang
    Wang, Guan
    Sun, Hongye
    Qian, Ziliang
    Tan, Yexiong
    Qin, Yuxin
    Shen, Yuhong
    Xu, Xiaowei
    Chen, Shu-Hui
    Chan, Chi-Chung
    Wang, Hongyang
    Mao, Mao
    Fang, Douglas D.
    ONCOTARGET, 2016, 7 (05) : 5461 - 5469
  • [24] EFFICACY AND SAFETY OF GLPG0634, A SELECTIVE JAK1 INHIBITOR, AFTER SHORT-TERM TREATMENT OF RHEUMATOID ARTHRITIS; RESULTS OF A PHASE IIA TRIAL
    Vanhoutte, F. P.
    Mazur, M.
    Namour, F.
    van der Aa, A.
    Wigerinck, P.
    van 't Klooster, G. A. E.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 145 - 145
  • [25] Phase 1 and Phase 2 Data Confirm That GLPG0634, a Selective JAK1 Inhibitor, Has a Low Potential for Drug-Drug Interactions.
    Florence, Namour
    Julie, Desrivot
    Van der Aa, Annegret
    Tasset, Chantal
    van 't Klooster, Gerben
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S651 - S651
  • [26] Author’s Reply to Srinivas: “Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection”
    Florence Namour
    Clinical Pharmacokinetics, 2015, 54 : 1297 - 1298
  • [27] Author's Reply to Srinivas: "Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection"
    Namour, Florence
    CLINICAL PHARMACOKINETICS, 2015, 54 (12) : 1297 - 1298
  • [28] Exploration of GLPG0634, the First Selective JAK1 Inhibitor, in Inflammatory Bowel Disease Is Supported by Early Clinical Results and Mouse DSS-Colitis Data
    Galien, Rene
    Merciris, Didier
    Vanhoutte, Frederic P.
    Delachaume, Carole
    Namour, Florence S.
    Vayssiere, Beatrice
    Van der Aa, Annegret
    Brys, Reginald
    van't Klooster, Gerben A.
    GASTROENTEROLOGY, 2014, 146 (05) : S49 - S49
  • [29] Treatment of Rheumatoid Arthritis Patients with the JAK1-Selective Inhibitor GLPG0634 Reverses an Arthritis-Specific Blood Gene Signature to Healthy State.
    Ongenaert, Mate
    Dupont, Sonia
    Vayssiere, Beatrice
    Brys, Reginald
    Van Rompaey, Luc
    Menet, Christel
    Galien, Rene
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S657 - S658
  • [30] Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor Is Effective As Monotherapy in Patients with Active Rheumatoid Arthritis: Results from a Phase 2B Dose Ranging Study
    Kavanaugh, Arthur
    Ponce, Lucia
    Cseuz, Regina
    Reshetko, Olga
    Stanislavchuk, Mykola A.
    Greenwald, Maria
    Van der Aa, Annegret
    Vanhoutte, Frederic
    Tasset, Chantal
    Harrison, Pille
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
12345